What Happened to Hims Compounded GLP-1s? The Novo Lawsuit Explained
Key Takeaways
- Hims (Hims & Hers Health) offered compounded semaglutide as one of their highest-revenue products
- Novo Nordisk sued to stop unauthorized use of its semaglutide patents and trademarks
- The lawsuit, combined with FDA regulatory tightening, forced Hims to exit compounded semaglutide
- This is part of a broader pattern: brand-name manufacturers pushing back against the compounding market
- Other telehealth companies have faced similar pressure — the Hims case is the most visible example
When Hims stopped offering compounded semaglutide, it made national news. The company had built significant revenue around the product, and its removal affected hundreds of thousands of patients. Here's what happened and what it signals about the compounding market.
The Novo Nordisk Strategy
Novo Nordisk pursued a multi-pronged approach:
- Intellectual property claims: Semaglutide is protected by multiple patents and trademarks
- FDA advocacy: Novo pushed for semaglutide's removal from the drug shortage list, eliminating the 503B compounding basis
- Direct legal action: Lawsuits against specific telehealth companies and compounding pharmacies
- Pricing response: NovoCare self-pay programs ($149–$349/mo) aimed to compete with compounded pricing
What This Means for Other Providers
The Hims case established a precedent that brand-name manufacturers will aggressively protect their GLP-1 market. Smaller telehealth providers face the same legal risk if they compound semaglutide through channels that don't meet 503A patient-specific standards.
The providers that survive this environment are those operating cleanly under 503A with patient-specific prescriptions, licensed pharmacies, and proper legal frameworks.
Embody
GLP-1 · LeadCompounded injectable semaglutide. Established program, strong clinical support. Lead anchor provider.
Operating under 503A patient-specific model.
Gala
GLP-1Compounded injectable semaglutide at $179/month flat pricing. Injection-only.
Telos Rx
TirzCompounded tirzepatide. First month from $40; ongoing $160-249/mo.
The Hims case is a warning signal, not an endpoint. Compounded semaglutide remains available through properly licensed 503A providers — but the legal and commercial pressure from brand-name manufacturers is real and ongoing. Patients should use providers with clear 503A compliance, not those that might be one lawsuit away from shutting down.
GLP-1 Compound Pharmacy Editorial
Independent compounding pharmacy research. 503A/503B analysis, safety verification, regulatory tracking. Not medical advice.